Search
Brigatinib
go.drugbank.com/drugs/DB12267ApprovedInvestigationalBrigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It ...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesAducanumab
go.drugbank.com/drugs/DB12274ApprovedInvestigationalAducanumab, or BIIB037, is a monoclonal IgG1 antibody that targets extracellular amyloid-β plaques in the brain; similar to gantenerumab, bapineuzumab and solanezumab. Aducanumab is a recombinant antibody derived from patients with slow ...
Propiverine
go.drugbank.com/drugs/DB12278ApprovedPropiverine is a widely used antimuscarinic drug with a mixed mode of action in the treatment of symptoms associated with overactive bladder (OAB) . Overactive bladder (OAB) is a chronic condition of the lower urinary tract characterized...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesEravacycline
go.drugbank.com/drugs/DB12329ApprovedInvestigationalEravacycline, known as Xerava by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive aerobic, and facultative bacte...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesLynestrenol
go.drugbank.com/drugs/DB12474ApprovedWithdrawnLynestrenol is a progestin and prodrug of norethisterone.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 InhibitorsCopanlisib
go.drugbank.com/drugs/DB12483ApprovedInvestigationalCopanlisib is a selective pan-Class I phosphoinositide 3-kinase (PI3K) inhibitor with preferential activity against the alpha and delta isoforms. PI3K, a lipid kinase that activates downstream signalling pathways involved in cell surviva...
Categories: Cytochrome P-450 CYP1A1 Substrates, P-glycoprotein substrates1,2-Benzodiazepine
go.drugbank.com/drugs/DB12537ApprovedInvestigationalWithdrawnBenzodiazepine is under investigation for the prevention of Delirium and C.Surgical Procedure; Cardiac. Benzodiazepine has been investigated for the treatment of Obesity, Sleep Apnea, Obstructive, and Disorders of Gallbladder, Biliary Tr...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSamidorphan
go.drugbank.com/drugs/DB12543ApprovedInvestigationalOlanzapine is an effective atypical antipsychotic that, like other antipsychotics, is associated with weight gain, metabolic dysfunction, and increased risk of type II diabetes. Samidorphan is a novel opioid antagonist structurally relat...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesSparsentan
go.drugbank.com/drugs/DB12548ApprovedInvestigationalSparsentan is a dual antagonist of the endothelin type A receptor (ETAR) and the angiotensin II (Ang II) type 1 receptor (AT1R) with a similar affinity for both (9.3 nM for ETAR and 0.8 nM for AT1R). Sparsentan is first in its class and ...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesPiperine
go.drugbank.com/drugs/DB12582InvestigationalBioperine has been used in trials studying the treatment of Multiple Myeloma and Deglutition Disorders.
Categories: Cytochrome P-450 CYP3A Inhibitors, P-glycoprotein inhibitors